Trials / Completed
CompletedNCT03916458
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (ATILA STUDY)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 62 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Days
- Healthy volunteers
- Not accepted
Summary
Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to clinical practice who obtained a complete response (CR) to treatment in one of these 2 situations: 1. Complete response (CR) obtained exclusively with first-line sunitinib treatment (sunitinib CR). 2. Response obtained after a period of time on treatment with sunitinib in which local treatment was also performed (surgery of the residual metastasis/metastases, radiofrequency ablation or radiotherapy) to achieve the total macroscopic disappearance of the disease, according to the opinion of the physician responsible for the patient (CR + local treatment).
Conditions
Timeline
- Start date
- 2019-12-17
- Primary completion
- 2020-11-03
- Completion
- 2020-11-03
- First posted
- 2019-04-16
- Last updated
- 2021-12-13
- Results posted
- 2021-12-13
Locations
31 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT03916458. Inclusion in this directory is not an endorsement.